Study of Magrolimab in Participants With Solid Tumors
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are to evaluate the safety, tolerability, and recommended
Phase 2 dose (RP2D) of magrolimab + docetaxel combination therapy in solid tumors (Safety
Run-in Cohort 1, Phase 2 Cohorts 1a,
1b, and 1c) and to evaluate the efficacy of magrolimab + docetaxel combination therapy in
solid tumors as determined by investigator-assessed objective response rate (ORR) (Phase 2
Cohorts 1a, 1b, and 1c)